Inhibitors that target BTK (BTKi) have emerged as breakthrough therapies for treating a variety of B-cell malignancies, such as chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, and Waldenström’s macroglobulinemia (12, 13, 14). Here, BTK is linked to B-cell chronic lymphocytic leukemia.